The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

Last Modified: Mar 18, 2026 @ 9:47 AM

Program Description

Join us for the highly anticipated IAS–USA annual course in Atlanta, Georgia, for the most current and clinically relevant information in HIV care, including practice-changing data presented at the Conference on Retroviruses and Opportunistic Infections (CROI). Don’t miss out on the opportunity to engage with faculty and peers in person and to stay at the forefront of what’s new in HIV management. This dynamic live course will be held in person at a new location at the Loudermilk Conference Center, and there will NOT be a simultaneous virtual component for this course.

This in-person course will highlight updates from CROI 2025; new antiretroviral formulations and strategies; ulcerative sexually transmitted infections (STIs), including syphilis, herpes simplex virus (HSV), mpox, and others; primary care issues around HIV care HIV; review of the current state and understanding of long-acting drugs for the treatment and prevention of HIV; and a case-based panel discussion on antiretroviral therapy. This course will also discuss overall weight management, including recent studies of glycoprotein-1 receptor agonist (GLP-1 RA) use among people with HIV and updates on hepatitis B cure.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs
• Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
• Implement updated primary care recommendations
• Identify available treatment options for managing weight gain, including recent studies of GLP-1RAs use among people with HIV, and describe potential clinical challenges with GLP-1RA use
• Recognize the clinical presentations of ulcerative STIs, including HSV, mpox, syphilis, and others
• Describe the current state of hepatitis B elimination progress in the US and across the globe

Topics

• Key Updates from CROI 2025
• New antiretroviral formulations and strategies
• Ulcerative STIs
• Primary care issues around HIV care
• HIV prevention, including long-acting drugs
• Hepatitis B cure
• Weight management, including the use of GLP-1RA use
• Difficult cases in antiretroviral therapy

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.